• VIRAL HEPATITIS •

Targeted ribonuclease can inhibit replication of hepatitis B virus

Jun Liu, Ying-Hui Li, Cai-Fang Xue, Jin Ding, Wei-Dong Gong, Ya Zhao, Yu-Xiao Huang

Jun Liu, Ying-Hui Li, Cai-Fang Xue, Jin Ding, Wei-Dong Gong, Ya Zhao, Yu-Xiao Huang, Department of Pathogenic Organism, Fourth Military Medical University, Xi' an 710033, Shaanxi Province, China
Supported by National Natural Science Foundation of China, No. 30100157, Medical Research Fund of PLA, No. 01MA184, and Innovation Project of FMMU, No. CX99005
Correspondence to: Dr. Jun Liu or Prof Cai-Fang Xue, Department of Pathogenic Organism, Fourth Military Medical University, Xi' an 710033, Shaanxi Province, China. etiology@fmmu.edu.cn
Received: 2002-07-17   **Accepted:** 2002-08-07

Abstract

AIM: To study the effect of a novel targeted ribonuclease (TN), the fusion protein of HBVc and human eosinophil-derived neurotoxin (hEDN), on the HBV replication *in vitro*.

METHODS: The gene encoding the targeted ribonuclease was cloned into pcDNA3.1 (-) to form recombinant eukaryotic expression vector p/TN. Control plasmids, including p/hEDN, p/HBVc, and p/TNmut in which a Lys113→Arg mutation was introduced by sequential PCR to eliminate the ribonuclease activity of hEDN, were also constructed. Liposome-mediated transfection of 2.2.15 cells by p/TN, p/TNmut, p/hEDN, p/HBVc, and pcDNA3.1 (-), or mock transfection was performed. After that, RT-PCR was used to verify the transgene expression. Morphology of the transfected cells was observed and MTT assay was performed to detect the cytotoxicity of transgene expression. Concentration of HBsAg in the supernatant of the transfected cells was measured using solid-phase radioimmunoassay.

RESULTS: Transgenes were successfully expressed in 2.2.15 cells. No obvious cytotoxic effect of transgene expression on 2.2.15 cells was found. The HBsAg concentration in the p/TN transfected cells was reduced by 58 % compared with that of mock transfected cells. No such an effect was found in all other controls.

CONCLUSION: The targeted ribonuclease can inhibit HBV replication *in vitro* while it has no cytotoxicity on host cells. The targeted ribonuclease may be used as a novel antiviral agent for human HBV infection.

INTRODUCTION

Hepatitis B virus (HBV) infection is still a major health concern around the world. Globally, more than 350 million people are infected by HBV, and some of them will evolve into liver cirrhosis and hepatocellular carcinoma (HCC)[1-3]. Although vaccination can elicit effective immunity in about 95 % of inoculated people, the non-responders to vaccination who may contact HBV infection in their life, the threat of escape mutants, and the huge amount of currently infected people call for an effective treatment[4-6]. Interferon-α (IFN-α) is the first choice for the treatment of chronic HBV infection. However, the sustained response rate to IFN-α treatment is only about 30 %[7]. IFN-α can also cause many adverse effects, such as fatigue, fever, neutropenia, autoimmune disease, psychological problems, and so on[8]. Nucleotide analogues such as lamivudine can inhibit replication of HBV *via* inhibiting the synthesis of minus-strand DNA of HBV, but cease of the treatment usually leads to relapse of the infection and drug-resistant virus variants have emerged[9-11]. Antisense nucleotides and ribozymes have been reported to suppress HBV replication *in vitro*[12-17]. However, up to now, antisense nucleotides and ribozymes can generally only moderately inhibit HBV replication intracellularly. In a word, the limited efficacy of current treatment for HBV infection justifies the search for new treatment strategy.

Capsid-targeted viral inactivation (CTVI), first proposed by Natsoulis and Boeke in 1991, is a conceptually powerful antiviral approach[18]. The principle of CTVI is to construct a fusion protein of viral capsid protein and some degradative enzyme. The capsid part of the fusion protein serves to target the degradative enzyme to virions and the degradative enzyme can specifically destruct the component of the virions. The degradative enzymes used presently are nucleases though other enzymes such as lipases and proteinases can also be used in CTVI in principle. CTVI has been thoroughly investigated in the experimental treatment for retrovirus, such as Moloney murine leukemia virus (MMLV) and HIV, showing a promising prospect as an antiviral treatment[19-26].

The replication of Hepadnavirus, including HBV, is unique in DNA virus in that it needs a RNA intermediate and a reverse transcription process[1]. This 3.5 kb RNA intermediate contains all genetic information of HBV and is so called pregenomic RNA (pgRNA). The pgRNA is first translated to both the capsid, or core, protein (c protein) and the DNA polymerase protein (P protein). Then the pgRNA is bound first by P protein and cellular chaperones to form a complex which is then encapsidated by C protein[27-29]. Inside the nucleocapsids, P protein catalyzes the synthesis of minus-strand DNA via reverse transcription and then the incomplete plus-strand DNA. The nucleocapsids containing minus- and plus-strand DNA can reenter nucleus or bud into endoplasmic reticulum and then be released via secretory pathway out of host cells[30]. C-terminal 144-164 amino acids of C protein, rich in arginine, is necessary for pregenome encapsidation since particles formed by C mutant deleting this domain contain no pgRNA[31].

The replication characteristic of HBV hints CTVI can also be applied to this malicious virus. Previously, we reported the construction of a fusion protein of HBV C protein and a ribonuclease, human eosinophil-derived neurotoxin (hEDN)[32-34]. In this paper, we found that this fusion protein, which was named as targeted ribonuclease in this paper, could effectively inhibit the replication of HBV, while had no cytotoxicity on host cells.

MATERIALS AND METHODS

Cell culture

2.2.15 cell line, human hepatoblastoma Hep G2 cell line stably transfected by HBV genome[35-37], was kindly provided by Dr.

Cheng (Chinese PLA 302 Hospital) and cultured in Dulbecco's modified Eagle's medium (DMEM, purchased from Gibco Life Technologies, Grand Island, NY) supplemented with 100 mL/L fetal calf serum (Sijiqing Biotech Company, Hangzhou).

Plasmid construction

Targeted ribonuclease eukaryotic expression plasmid p/TN (Figure 1) and control plasmids p/hEDN and p/HBVc were constructed with the method previously reported[34]. Briefly, cDNA coding for hEDN or HBVc was amplified by RT-PCR from the total RNA isolated from HL60 cell line (kindly provided by Professor Boquan Jin, Department of Immunology, Fourth Military Medical University) or 2.2.15 cell line. Then, the PCR product was cloned into pUC18. After verification of the correctness of the open reading frames of the cloned hEDN and HBVc by sequencing, they were subcloned into pcDNA3.1 (-) (Gibco Life Technologies), to generate p/hEDN and p/HBVc, respectively, or they were ligated together by T4 ligase (Gibco Life Technologies) and the ligated DNA fragment was cloned into pcDNA3.1 (-) to form p/TN. To construct control plasmid p/TNmut in which the DNA fragment encoding hEDNmut (hEDN mutated for just one amino acid, Lys113→Arg, which eliminates the ribonuclease activity[38]) substituted for hEDN in p/TN, sequential PCR was used to obtain hEDNmut-encoding DNA fragment (Figure 2). For the first round of two separate PCR reactions, primers M1, N2 and M2, N1 (all synthesized by Sangon Company, Shanghai) were used, respectively, and pUC18/hEDN was used as template. The sequences of the primers are as follows:

N1: 5'-GCA GAA ACC AAA ATA CTT TCC T-3'
N2: 5'-TCT GCA TCG CCG TTG ATA ATT-3'
M1: 5'-GCG CGG ATC CAC CAT GAA ACC TCC ACA GTT TAC-3'
M2: 5'-GCG CGA GCT CGA TGA TTC TAT CCA GGT G-3'

The underlined nucleotides in N1 and N2 were used to introduce the mutation. The PCR products of the two reaction were mixed together. Two μL of the mixture was used as the template, M1 and M2 were used as primers for the next round of PCR. The PCR product of this round amplification was cloned into pUC18 and sequenced for confirmation of the mutation. Then the hEDNmut gene was subcloned into p/TN to substitute hEDN gene to generate recombinant plasmid p/TNmut. pcDNA3.1(-)/GFP was generated by transferring green fluorescent protein (GFP) gene from pEGFP-N3 MCS (Clontech, Palo Alto, CA) into pcDNA3.1(-).


Figure 1 Construction of p/TN. cDNA coding for hEDN or HBVc was amplified by RT-PCR, ligated together, and then cloned into pcDNA3.1 (-) to form p/TN.


Figure 2 Generation of hEDNmut gene by sequential PCR. For PCR 1 and 2, pUC18/hEDN was used as template. Primers pair M1 and N2 were used in PCR 1 and N1 and M2 in PCR 2. For PCR 3, the mixture of PCR 1 and 2 product was used as template and M1 and M2 as primers. The black dots in the figure denote the nucleotides introducing the Lys113→Arg mutation which eliminates the ribonuclease activity.

Transfection

Twenty-four h before transfection, 2.2.15 cells were seeded into the culture plate at a density of 2×10^8/L. Lipofectamine™ 2000 reagent (Gibco Life Technologies) was used for the transfection of 2.2.15 cells by p/TN, p/TNmut, p/hEDN, p/HBVc, pcDNA3.1 (-), or mock solution (DMEM plus Lipofectamine™ 2000 reagent containing no plasmid) according to the manufacturer's protocol. The amount of Lipofectamine™ 2000 reagent (approximately 3.1 μL/cm² surface area in this study) and the concentration of DNA (approximately 1 μg/cm² surface area in this study) were first optimized in a preliminary transfection of 2.2.15 cells by pcDNA3.1(-)/GFP in which GFP gene was used as a reporter gene.

Confirmation of transgene expression by RT-PCR

Forty-eight h after the transfection, total RNA was isolated from transfected 2.2.15 cells using Trizol®reagent (Gibco Life Technologies) according to the manufacturer's protocol. One μL of total RNA was used as template. RT-PCR was performed using SuperScript™ One-step RT-PCR kit (Gibco Life Technologies) as recommended by the manufacturer. Forward primer was T7 promoter primer which is upstream to the multicloning site of pcDNA3.1 (-). Reverse primer was complementary to pcDNA3.1/BGH reverse priming site which is downstream to multicloning site of pcDNA3.1 (-). The sequences of the two primers are as follows:
Forward primer: 5'-TAA TAC GAC TCA CTA TAG GGA GA-3'
Reverse primer: 5'-TAG AAG GCA CAG TCG-3'

The condition of RT-PCR was: 50 ℃ 30 min, 94 ℃ 2 min, then 40 cycles at 94 ℃ 30 s, 60 ℃ 30 s, and 72 ℃ 2 min. To ensure that the amplified product was from RNA, but not DNA, a control was set up for each RT-PCR reaction, in which the reverse transcriptase was omitted.

Quantification of HBsAg in supernatant of cell culture

Forty-eight h after the transfection, the supernatant of the cell culture was collected, and HBsAg in the supernatant was quantified using the Solid Phase Radio-immunoassay Kit for Quantification of HBsAg (Beimian Dongya Biotech Institute, Beijing) according to the manufacturer's protocol. Briefly, 200 μL of the supernatant was incubated with plastic bead coated by anti-HBs Ab at 45 ℃ for 1.5 h. After thorough washing, the bead with deionized water, 200 μL of ^{125}I-labelled secondary antibody was added and incubated at room

temperature overnight. The bead was thoroughly washed, and cpm was measured. The concentration of HBsAg of each sample was obtained by comparing the cpm of each sample with a standard curve.

MTT assay

Forty-eight h after the transfection, 20 μL of MTT solution (the concentration of MTT was 5 g/L) was added to each well and the culture plate was incubated at 37 ℃ for 4 h, then 150 μL of DMSO was added to each well and the plate was shaken for 10 min. The A_{490} value of each well was obtained by an ELISA reader.

Statistical analysis

Variance analysis and Student's *t* test were used for data analysis. Differences were considered significant when $P<0.05$.

RESULTS

Transgene expression in 2.2.15 cells

As shown in Figure 3, the results of the RT-PCR indicated that the transgenes were expressed in transfected 2.2.15 cells.


Figure 3 Confirmation of transgenes expression in transfected 2.2.15 cell line. Forty-eight h after the transfection, total RNA was isolated from transfected 2.2.15 cells and RT-PCR was performed to confirm the expression of transgenes. The RT-PCR products were then electrophoresed in 1.2 % agarose gel. Lanes 1-5 represent the RT-PCR results for total RNA isolated from 2.2.15 cells transfected by p/TN, p/TNmut, p/HBVc, p/hEDN, and pcDNA3.1 (-), respectively. Lanes 6-10 represent controls corresponding to lanes 1-5, respectively, in which reverse transcriptase was omitted in RT-PCR. M: DNA Marker (2000, 1000, 750, 500, 250, 100bp from top to bottom).

The effect of targeted ribonuclease on cell viability

The morphological alterations of the transfected 2.2.15 cells were observed under microscope. There were no discernible morphological differences of 2.2.15 cells transfected with p/TN, as compared with the controls (Figure 4). To further analyze the effect of targeted ribonuclease on cell viability, MTT assay was performed. The A_{490} value of 2.2.15 cells transfected with p/TN, p/hEDN, p/HBVc, p/TNmut, pcDNA3. 1 (-), and mock transfection was 0.425±0.065, 0.465±0.050, 0.410±0.075, 0.438±0.042 0.413±0.063, and 0.430±0.065, respectively ($\bar{x}±s$, $n=4$).

There were no significant differences between A_{490} value of 2.2.15 cells transfected with p/TN and those of controls ($P>0.05$). Taken together, these results indicated that the targeted ribonuclease had no adverse effects on cell viability and proliferation.

Inhibition of HBV replication by targeted ribonuclease

As shown in Figure 5, the concentration of HBsAg in the supernatant of 2.2.15 cells transfected with p/TN was significantly lower than controls ($P<0.05$), while that of 2.2.15 cells transfected with p/TNmut, p/hEDN, p/HBVc, pcDNA3.1 (-), or mock transfection did not significantly different from each other ($P>0.05$). Compared with that of mock transfected

2.2.15 cells, the concentration of HBsAg in the supernatant of 2.2.15 cells transfected with p/TN was decreased by 58 %.


Figure 4 Morphology of 2.2.15 cells 48 h after transfection. A-F represent 2.2.15 cells transfected by p/TN, p/hEDN, p/HBVc, p/TNmut, pcDNA3.1 (-), or mock transfection, respectively. There were no discernible morphological differences of 2.2.15 cells transfected with p/TN, as compared with the controls.


Figure 5 The HBsAg concentration in supernatants of transfected 2.2.15 cells. Groups A-F represent 2.2.15 cells transfected by p/TN, p/hEDN, p/HBVc, p/TNmut, pcDNA3.1 (-), or mock transfection, respectively. The concentration of HBsAg in the supernatant of 2.2.15 cells transfected with p/ TN was decreased by 58 % as compared with that of mock transfected 2.2.15 cells.

DISCUSSION

Theoretically, CTVI has many advantages in the treatment of viral infection[39]. First, CTVI is highly specific. This high specificity is conferred by the encapsidating capacity and self-assembly property of the viral capsid protein which is used as a targeting molecule in CTVI. Second, CTVI is highly efficient. The nuclease, which is used as an effector molecule in CTVI, is a protein enzyme, and its catalytic efficiency is higher than ribozyme. Third, escape mutants may rarely if not impossibly arise in case of CTVI since viral capsid proteins generally play important roles in virus assembly and infection. Fourth, while

ribozyme and antisense RNA can only be used clinically in the form of gene therapy, CTVI can be used in the form of either gene therapy or recombinant protein drug. The results of experimental research also indicate that CTVI is a promising antiviral strategy. Boeke *et al*. reported that the fusion protein of Gag of murine Moloney leukemia virus (MMLV) and staphylococcus nuclease could reduce the infection titer of MMLV by 20-60 %, while that of Gag and ribonuclease H1 of *E. coli* could inhibit the production of MMLV by 97-99 %[21,24]. Recently, Schumann *et al*. tested the antiviral effect of CTVI *in vivo* using transgenic murine models[26]. They found Gag-nuclease fusion protein could significantly inhibit MMLV replication, ameliorate the symptoms, and increase the life span up to 2.5 fold in transgenic mice. Furthermore, they found that the fusion protein was nontoxic for transgenic mice, confirming the previous *in vitro* cell culture results[19-25]. In this report, we demonstrated that targeted ribonuclease constructed by us (the fusion protein of HBVc and hEDN) could reduce the concentration of HBsAg in the supernatant of the transfected 2.2.15 cells by 58 %. Although it is controversial that the decrease of HBsAg concentration is caused by some factors other than the inhibition of HBV replication by targeted ribonuclease, our results strongly disprove this argument. First, the fact that transfection of p/TN decreased HBsAg concentration in the supernatant while p/HBVc and p/TNmut, which are identical to p/TN except for only one amino acid mutation but lose ribonuclease activity, indicates that the reduction of HBsAg is dependent on the activity of the ribonuclease in the fusion protein targeted ribonuclease. Second, transfection of p/hEDN did not affect the HBsAg concentration, showing that the reduction of HBsAg relies on the existence of HBVc in the fusion protein. Our present results are most consistent with a model that the targeted ribonuclease encapsidates the pgRNA together with wild type capsid protein and then degrades it (also see below). This model has been corroborated by some recent research reports[19-26, 40]. On the other hand, 58 % reduction of HBsAg in the supernatant of 2.2.15 cells caused by the targeted ribonuclease might be an underestimate for the inhibition of HBV replication since besides present in mature virions as envelope protein, a large amount of HBsAg was synthesized and secreted as 22 nm spherical and filamentous particles by 2.2.15 cells using 2.1kb HBV mRNA as transcript which, unlike pgRNA, can not be encapsidated and therefore may not be degraded by the targeted ribonuclease[35,37]. Therefore, even if the targeted ribonuclease can strongly inhibit HBV replication, there might still be a large amount of HBsAg secreted extracellularly. The mechanism for the decrease of HBsAg concentration caused by the targeted ribonuclease might be as follows: the degradation of HBV pgRNA by targeted ribonuclease leads to the decrease of P and C protein of HBV since pgRNA also acts as mRNA for the translation of both proteins. The reduction of pgRNA, P and C protein will impair the assembly of viral capsid and then reduce the mature virions released from host cells. Further analysis including Northern and Southern blot is being performed in this laboratory to clarify the degree of inhibition on HBV replication by the targeted ribonuclease and to elucidate at what stage of HBV replication the targeted ribonuclease exerts its antiviral role.

In the process of this study, Beterams and Nassal reported their CTVI application for inhibition of HBV replication *in vitro*[40]. Although both their research and ours used the same strategy against HBV replication and both used HBVc as the target molecule, the effector molecules adopted were different. Bererams *et al*. used staphylococcal nuclease (SN) and we used hEDN. Compared with SN, hEDN may be more suitable for the treatment of HBV infection in human beings because as a human-origin molecule, hEDN will not induce specific immunity which may not only decrease the efficacy of CTVI but also induce immunopathological response. The difference of the effector molecules also means the targets of CTVI in the two studies were different. SN is generally believed to be active only extracellularly because it requires a high Ca^{2+} concentration present extracellularly but not intracellularly for its activity[41]. Therefore, SN-capsid protein incorporated into the virion is only active in degrading the viral nucleic acids upon release of the virion from the cell into an extracellular milieu[18-19, 21, 23, 25-26]. According to this scheme, the targeted SN in Beterams *et al*'s study can only degrade the relaxed circular (RC) DNA of mature virion released form the cell. Although they suggested in their reports that targeted SN might be mildly activated intracellularly by somewhat unknown mechanism and then cut pgRNA and minus-strand DNA of HBV, their results showed targeted SN had no significant effect on pgRNA. In contrast, the effector molecule in our study, hEDN, is a ribonuclease. Therefore, the target molecule degraded by the targeted ribonuclease constructed by us is most probably HBV pgRNA, the only RNA stage in the replication of HBV. As stated above, this notion is also supported by our experimental results, since the ribonuclease activity of hEDN is necessary for the anti-HBV effect of targeted ribonuclease. Similarly, onconase, an amphibian ribonuclease was reported to inhibit HIV replication intracellularly by degrading HIV RNA[42]. The degradation of HBV pgRNA will not only lead to less mature virions released from host cells, which means secreted viral particles had lower infectivity, but also inhibit the amplification of HBV closed circular DNA (cccDNA) which is downstream to pgRNA in HBV replication[43]. This inhibition on HBV cccDNA amplification is of pivotal significance for the treatment of chronic HBV infection since the amplification of cccDNA, the template for all HBV transcripts, plays a major role in the persistence of HBV in infected hepatocytes[1, 30].

In summary, we constructed a novel targeted ribonuclease which can specifically inhibit HBV replication but has no cytotoxicity for host cells. Our results raise the possibility of using the targeted ribonuclease as a therapeutic agent for human HBV infection. For this purpose, we are generating recombinant adenovirus vector carrying the targeted ribonuclease to test its antiviral efficacy in HBV murine model.

REFERENCES

1   **Ganem D,** Varmus HE. The molecular biology of the hepatitis B virus. *Annu Rev Biochem* 1987; **56:** 651-693

2   **Lau JY,** Wright TL. Molecular virology and pathogenesis of hepatitis B. *Lancet* 1993; **342:** 1335-1340

3   **Tang ZY.** Hepatocellular carcinoma. *World J Gastroenterol* 2001; **7:** 445-454

4   **Hoofnagle JH.** Therapy of viral hepatitis. *Digestion* 1998; **59:** 563-578

5   **Hilleman MR.** Overview of the pathogenesis, prophylaxis and therapeusis of viral hepatitis B, with focus on reduction to practical applications. *Vaccine* 2001; **19:** 1837-1848

6   **Francois G,** Kew M, Van Damme P, Mphahlele MJ, Meheus A. Mutant hepatitis B virus: a matter of academic interest only or a problem with far-reaching implications? *Vaccine* 2001; **19:** 3799-3815

7   **Wong DK,** Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B: a meta-analysis. *Ann Intern Med* 1993; **119:** 312-323

8   **Hoofnagle JH,** di Bisceglie AM. Treatment of chronic viral hepatitis. *N Engl J Med* 1997; **336:** 347-356

9   **Nevens F,** Main J, Honkoop P, Tyrrell DL, Barber J, Sullivan MT, Fevery J, De Mau RA, Thomas HC. Lamivudine therapy for chronic hepatitis B: A six-month randomized dose-ranging study. *Gastroenterology* 1997; **113:** 1258-1263

10   **Tipples GA,** Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrrell DL. Mutation in HBV RNA-dependent DNA polymerase confers resistance to lamivudine *in vivo. Hepatology* 1996; **24:** 714-717

11   **Santantonio T,** Mazzola M, Iacovazzi T, Miglietta A, Guastadisegni A, Pastore G. Long-term follow-up of patients with anti-HBe/HBV DNA-positive chronic hepatitis B treated for 12 months with lamivudine. *J Hepatol* 2000; **32:** 300-306

12   **Tung FYT,** Bowen SW. Targeted inhibition of hepatitis B virus gene expression: a gene therapy approach. *Front Biosci* 1998; **3:** a11-a15

13   **Zhoug S,** Wen SM, Zhang DF, Wang QL, Wang SQ, Ren H. Sequencing of PCR amplified HBV DNA pre-c and c regions in the 2.2.15 cells and antiviral action by targeted antisense oligonucleotide directed against sequence. *World J Gastroenterol* 1998; **4:** 434-436

14   **Song YH,** Lin JS, Liu NZ, Kong XJ, Xie N, Wang NX, Jin YX, Liang KH. Anti-HBV hairpin ribozyme-mediated cleavage of target RNA *in vitro. World J Gastroenterol* 2002; **8:** 91-94

15   **zu Putlitz J,** Wieland S, Blum HE, Wands JR. Antisense RNA complementary to Hepatitis B virus specifically inhibits viral replication. *Gastroenterology* 1998; **115:** 702-713

16   **zu Putlitz J,** Yu Q, Burke JM, Wands JR. Combinatorial screening and intracellular antiviral activity of hairpin ribozymes directed against Hepatitis B virus. *J Virol* 1999; **73:** 5381-5387

17   **Beck J,** Nassal M. Efficient hammerhead ribozyme-mediated cleavage of the structured hepatitis B virus encapsidation signal *in vitro* and in cell extracts, but not in intact cells. *Nucleic Acids Res* 1995; **23:** 4954-4962

18   **Natsoulis G,** Boeke JD. New antiviral strategy using capsid-nuclease fusion proteins. *Nature* 1991; **352:** 632-635

19   **Natsoulis G,** Seshaiah P, Federspiel MJ, Rein A, Hughes SH, Boeke JD. Targeting of a nuclease to murine leukemia virus capsids inhibits viral multiplication. *Proc Natl Acad Sci USA* 1995; **92:** 364-368

20   **Melekhovets YF,** Joshi S. Fusion with an RNA binding domain to confer target RNA specificity to an RNase: design and engineering of Tat-RNase H that specifically recognizes and cleaves HIV-1 RNA *in vitro. Nucleic Acids Res* 1996; **24:** 1908-1912

21   **Schumann G,** Qin L, Rein A, Natsoulis G, Boeke JD. Therapeutic effect of Gag-nuclease fusion protein on retrovirus-infected cell cultures. *J Virol* 1996; **70:** 4329-4337

22   **VanBrocklin M,** Ferris AL, Hughes SH, Federspiel MJ. Expression of a murine leukemia virus Gag-*Escherichia coli* RNase HI fusion polyprotein significantly inhibits virus spread. *J Virol* 1997; **71:** 3312-3318

23   **Wu X,** Liu H, Xiao H, Kim J, Seshaiah P, Natsoulis G, Boeke JD, Hahn BH, Kappes JC. Targeting foreign proteins to human immunodeficiency virus particles via fusion with Vpr and Vpx. *J Virol* 1995; **69:** 3389-3398

24   **Schumann G,** Cannon K, Ma WP, Crouch RJ, Boeke JD. Antiretroviral effect of a gag-RNase HI fusion gene. *Gene Ther* 1997; **4:** 593-599

25   **VanBrocklin M,** Federspiel MJ. Capsid-targeted viral inactivation can eliminate the production of infectious murine leukemia virus *in vitro. Virology* 2000; **267:** 111-123

26   **Schumann G,** Hermankova M, Cannon K, Mankowski JL, Boeke JD. Therapeutic effect of a Gag-nuclease fusion protein against retroviral infection *in vivo. J Virol* 2001; **75:** 7030-7041

27   **Hu J, T**oft DO, Seeger C. Hepadnavirus assembly and reverse transcription require a multi-component chaperone complex which is incorporated into nucleocapsids. *EMBO J* 1997; **16:** 59-68

28   **Junker-Niepmann M,** Bartenschlager R, Schaller H. A short cis-acting sequence is required for hepatitis B virus pregenome encapsidation and sufficient for packaging of foreign RNA. *EMBO J* 1990; **9:** 3389-3396

29   **Bartenschlager R,** Schaller H. Hepadnaviral assembly is initiated by polymerase binding to the encapsidation signal in the viral RNA genome. *EMBO J* 1992; **11:** 3413-3420

30   **Seeger C,** Mason WS. Hepatitis B virus biology. *Microbiol Mol Biol Rev* 2000; **64:** 51-68

31   **Nassal M.** The arginine-rich domain of the hepatitis B virus core protein is required for pregenome encapsidation and productive viral positive-strand DNA synthesis but not for virus assembly. *J Virol* 1992; **66:** 4107-4116

32   **Hamann KJ,** Barker RL, Loegering DA, Pease LR, Gleich GJ. Sequence of human eosinophil-derived neurotoxin cDNA: identity of deduced amino acid sequence with human nonsecretory ribonucleases. *Gene* 1989; **83:** 161-167

33   **Gleich GJ,** Loegering DA, Bell MP, Checkel JL, Ackerman SJ, McKean DJ. Biochemical and functional similarities between human eosinophil-derived neurotoxin and eosinophil Cationic protein: homology with ribonuclease. *Proc Natl Acad Sci USA* 1986; **83:** 3146-3150

34   **Li YH**, Liu J, Xue CF. Construction of HBV targeted ribonuclease and its expression in 2.2.15 cell line. *Xibao Yu Fenzi Mianyixue Zazhi* 2002; **18:** 217-220

35   **Sells MA,** Chen ML, Acs G. Production of hepatitis B virus particles in Hep G2 cells transfected with cloned hepatitis B virus DNA. *Proc Natl Acad Sci USA* 1987; **84:** 1005-1009

36   **Acs G,** Sells MA, Purcell RH, Price P, Engle R, Shapiro M, Popper H. Hepatitis B virus produced by transfected Hep G2 cells causes hepatitis in chimpanzees. *Proc Natl Acad Sci USA* 1987; **84:** 4641-4644

37   **Sells MA,** Zelent AZ, Shvartsman M, Acs G. Replicative intermediates of hepatitis B virus in Hep G2 cells that produce infectious virions. *J Virol* 1988; **62:** 2836-2844

38   **Rosenberg HF,** Dyer KD. Eosinophil cationic protein and eosinophil-derived neurotoxin. *J Biol Chem* 1995; **270:** 21539-21544

39   **Liu J,** Xue CF. Advances in the research of therapeutic ribonucleases. *Shengming Kexue* 2002; **14:** 139-140

40   **Beterams G,** Nassal M. Significant interference with hepatitis B virus replication by a core-nuclease fusion protein. *J Biol Chem* 2001; **276:** 8875-8883

41   **Tucker PW,** Hazen EE Jr, Cotton FA. Staphylococcal nuclease reviewed: a prototypic study in contemporary enzymology. I. Isolation; physical and enzymatic properties. *Mol Cell Biochem* 1978; **22:** 67-77

42   **Saxena SK,** Gravell M, Wu YN, Mikulski SM, Shogen K, Ardelt W, Youle RJ. Inhibition of HIV-1 production and selective degradation of viral RNA by an amphibian ribonuclease. *J Biol Chem* 1996; **271:** 20783-20788

43   **Tuttleman JS,** Pourcel C, Summers J. Formation of the pool of covalently closed circular viral DNA in hepadnavirus-infected cells. *Cell* 1986; **47:** 451-460

Edited by MaJY